Keyword: Fred Hutchinson Cancer Research Center
GlaxoSmithKline is joining forces with Lyell Immunopharma to boost the “fitness” of T cells treatments and improve their efficacy in solid tumors.
HighPassBio starts life with a phase 1 leukemia cell therapy and the support of a founder that raised $150 million to build a portfolio of startups.
The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.
Fred Hutch scientists used CRISPR-Cas9 to boost the production of fetal hemoglobin by targeting a specific population of stem cells.
Targeting DUX4 might improve the success of immunotherapies, scientists at Fred Hutchinson Cancer Research Center suggest.
A Fred Hutchinson team developed gold nanoparticles that can deliver CRISPR to mouse models of HIV and inherited blood disorders.
The week’s biotech discoveries included an I-O triple therapy against ovarian cancer and a single protein target for three diseases.
HIV mutates to evade immune antibodies that defend against pathogens. A Fred Hutch team has gained new insights into those mutations.
A Fred Hutch team has figured out how to kill dormant breast cancer cells using compounds that disrupt a protective signaling system.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
